Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial

Annals of Oncology

Volumn 25, Issue 5, 2014, Pages 1044-1052

  Barlesi, F ^a   Scherpereel, A ^b   Gorbunova, V ^c   Gervais, R ^d   Vikstrom A ^e   Chouaid, C ^f   Chella, A ^g   Kim, J H ^h   Ahn, M J ⁱ   Reck, M ^j   Pazzola, A ^k   Kim, H T ^l   Aerts, J G ^m   Morando, C ⁿ   Loundou, A ⁿ   Groen, H J M ^o   Rittmeyer, A ^p  

^a AIX MARSEILLE UNIVERSITY   (France)

^b LILLE UNIVERSITY HOSPITAL   (France)

^c N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^d CENTRE FRANÇOIS BACLESSE   (France)

^e Lungkliniken   (Sweden)

^f HÔPITAL SAINT ANTOINE   (France)

^g UNIVERSITY OF PISA   (Italy)

^h Yonsei University College of Medicine   (South Korea)

ⁱ Sungkyunkwan University School of Medicine   (South Korea)

^j KRANKENHAUS GROSSHANSDORF   (Germany)

^k SS Annunziata Hospital   (Italy)

^l National Cancer Center   (South Korea)

^m AMPHIA HOSPITAL   (Netherlands)

ⁿ ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^o UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^p Lungenfachklinik Immenhausen   (Germany)

more..

Author keywords

bevacizumab; chemotherapy; maintenance; nonsmall cell lung cancer; nonsquamous; pemetrexed

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CISPLATIN; GLUTAMIC ACID DERIVATIVE; GUANINE; MONOCLONAL ANTIBODY; PEMETREXED;

ADENOCARCINOMA; AGED; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; KAPLAN MEIER METHOD; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; MORTALITY; PHASE 3 CLINICAL TRIAL; PROPORTIONAL HAZARDS MODEL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; GLUTAMATES; GUANINE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84905822586     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu098     Document Type: Article

References (22)

1. Schiller, J.H., Harrington, D., Belani, C.P., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002), 92–98.
2. Breathnach, O.S., Freidlin, B., Conley, B., et al. Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results. J Clin Oncol 19 (2001), 1734–1742.
3. Sandler, A., Gray, R., Perry, M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355 (2006), 2542–2550.
4. Reck, M., von Pawel, J., Zatloukal, P., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL. J Clin Oncol 27 (2009), 1227–1234.
5. Reck, M., von Pawel, J., Zatloukal, P., et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL). Ann Oncol 21 (2010), 1804–1809.
6. Patel, J.D., Hensing, T.A., Rademaker, A., et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol 27 (2009), 3284–3289.
7. Leon, L., Vázquez, S., Gracia, J.M., et al. First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients. Expert Opin Pharmacother 13 (2012), 1389–1396.
8. Stevenson, J.P., Langer, C.J., Somer, R.A., et al. Phase 2 trial of maintenance bevacizumab alone after bevacizumab plus pemetrexed and carboplatin in advanced, nonsquamous nonsmall cell lung cancer. Cancer 118 (2012), 5580–5587.
9. Scagliotti, G.V., Parikh, P., von Pawel, J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26 (2008), 3543–3551.
10. Paz-Ares, L., De Marinis, F., Dediu, M., et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 13 (2012), 247–255.
11. Paz-Ares, L., De Marinis, F., Dediu, M., et al. PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately following induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 31 (2013), 2895–2902.
12. Ciuleanu, T., Brodowicz, T., Zielinski, C., et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 374 (2009), 1432–1440.
13. Barlesi, F, Scherpereel, A, Rittmeyer, A, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089). J Clin Oncol 31 (2013), 3004–3011.
14. Lababede, O., Meziane, M.A., Rice, T.W., TNM staging of lung cancer: a quick reference chart. Chest 115 (1999), 233–235.
15. Rittmeyer, A, Gorbunova, V, Vikstrom, A, Health-related quality of life in patients with advanced nonsquamous non-small-cell lung cancer receiving bevacizumab or bevacizumab-plus-pemetrexed maintenance therapy in AVAPERL (MO22089). J Thorac Oncol 8 (2013), 1409–1416.
16. Patel, J., Socinski, M.A., Garon, E.B., et al. A randomized, open-label, phase 3, superiority study of pemetrexed (Pem)+carboplatin (Cb)+bevacizumab (B) followed by maintenance Pem+B versus paclitaxel (Pac)+Cb+B followed by maintenance B in patients (pts) with stage IIIB or IV non-squamous non-small cell lung cancer (NS-NSCLC). J Thorac Oncol, 7, 2012, S336 (Abstr LBPL1).
17. Patel, J.D., Garon, E.B., Ramaswamy, G., et al. Exploratory analyses of efficacy and safety of pemetrexed (pem) plus bevacizumab (bev) and bev alone as maintenance therapy (MT) in patients (pts) with stage IIIb or IV nonsquamous non-small cell lung cancer (ns-NSCLC). J Clin Oncol, 31(suppl), 2013, 489s (Abstr 8012).
18. Zinner, R.G., Ross, H.J., Weaver, R., et al. Randomized, open-label, phase III study of pemetrexed plus carboplatin (PemC) followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab (PCB) followed by maintenance bevacizumab in patients with advanced nonsquamous (NS) non-small cell lung cancer (NSCLC). J Clin Oncol, 31(suppl), 2013 abstr LBA8003).
19. Dahlberg, S.E., Ramalingam, S.S., Belani, C.P., et al. A randomized phase III study of maintenance therapy with bevacizumab (B), pemetrexed (Pm), or a combination of bevacizumab and pemetrexed (BPm) following carboplatin, paclitaxel and bevacizumab (PCB) for advanced nonsquamous NSCLC: ECOG trial 5508 (NCT01107626). J Clin Oncol, 29(suppl), 2011, 36s (Abstr TPS218).
20. Little, A.G., Gay, E.G., Gaspar, L.E., et al. National survey of non-small cell lung cancer in the United States: epidemiology, pathology, and patterns of care. Lung Cancer 57 (2007), 253–260.
21. Wong, D.W., Leung, E.L., So, K.K., et al. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115 (2009), 1723–1733.
22. Bell, D.W., Lynch, T.J., Haserlat, S.M., et al. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23 (2005), 8081–8092.